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Available online xxxxBecker muscular dystrophy (BMD) is a dystrophinopathy caused by mutations in the dystrophin gene on chro-
mosome Xp21. BMD mutations result in truncated semi-functional dystrophin isoforms. Consequently, less se-
vere clinical symptoms become apparent later in life compared to Duchenne muscular dystrophy. Dermal
ﬁbroblasts from a BMD patient were electroporated with episomal plasmids containing reprogramming factors
to create the induced pluripotent stem cell line: CCMi002BMD-A-9 that showed pluripotent markers, were kar-
yotypically normal and capable of trilineage differentiation. MLPA analyses performed on DNA extracted from
CCMi002BMD-A-9 showed an in-frame deletion of exons 45 to 55 (CCMi002BMD-A-9 Δ45-55).
© 2018 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(continued)Resource table.N
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orderwhich arises due tomutations in the dystrophin gene. BMDoccurshttp://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CCMi002BMD-A-9 Δ45-55 summary information, chracterisation and quality control analyses.
Classiﬁcation Test Result Data
Morphology Photography Normal morphology. Fig. 1A
Phenotype Immunocytochemisty Assess expression of the pluripotency markers: SSEA4 and Tra-1-60. Fig. 1B
Flow cytometry Expression of the pluripotent cell surface marker Tra-1-60: 75%+ve Fig. 1C
Genotype Karyotype (Q-banding) and
resolution
e.g. 46XY, Resolution: 400 band level Fig. 1E
Identity Microsatellite PCR (mPCR) Not performed –
STR analysis and match e.g. 17 STR loci plus gender determining locus and matched against the ATCC STR database. Supplementary
material
Mutation analysis (if
applicable)
Sequencing Not performed –
MLPA Deletion of exons 45 to 55 from the DMD gene. Fig. 1F
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR: Negative. Supplementary
Fig. S1
Differentiation potential Directed differentiation Line expressed markers for each of the three germlayers: Nestin, ectoderm; αSMA, mesoderm,
and Sox17, endoderm.
Fig. 1D
Donor screening (optional) HIV 1+2 Hepatitis B,
Hepatitis C
Not performed
Genotype additional info
(optional)
Blood group genotyping Not performed
HLA tissue typing Not performed
22 A. Gowran et al. / Stem Cell Research 28 (2018) 21–24at one-third the incidence rate of Duchennemuscular dystrophy (DMD;
1:3802-1:6291 male births; Flanigan, 2012). BMD has a wide clinical
spectrum, from asymptomatic patients to those restricted to a wheel-
chair by age sixteen. Although the majority of patients survive to late
adulthood (50–60 years), many develop cardiomyopathy characterised
by a progressive decline in ejection fraction and early onset heart failure.
Certain exons of the dystrophin gene are more indispensable than
others for determining phenotype severity. BMD mutations preserve
the dystrophin reading frame thus permitting some degree of expres-
sion, albeit as truncated isoforms (Muntoni et al., 2003).
Following ethical approval and patient informed consent dermal ﬁ-
broblasts were isolated by explant culture of a skin biopsy obtained
from a 26-year-old man with BMD. To protect privacy, no identifying
patient information is included. The patient presented with an inciden-
tal ﬁnding of hyperkalemia at 15 years old. At time of biopsy the patient
was ambulant, however displayed reduced proximal strength in the
upper and lower limbs, and exertion-induced myalgia. The Becker
patient's ﬁbroblasts were reprogrammed into induced pluripotent
stem cells (iPSCs); (Table 1) by electroporation with plasmids encoding
L-MYC, LIN28, SOX2, KLF4, OCT4 (Okita et al., 2007) under feeder-free
deﬁned conditions. After 28 days of reprogramming, iPSC colonies
were selected and expanded. The iPSC line described here was named
CCMi002BMD-A-9 and entered further expansion and characterisation
for: pluripotent cell morphology (Fig. 1A), expression of pluripotency
proteins (SSEA4 and Tra-1-60; Fig. 1B) by immunoﬂuorescence.
CCMi002BMD-A-9 were 66% Tra-1-60 positive (Fig. 1C) as assessed by
FACS with no signiﬁcant differences compared to iPSC lines obtained
fromhealthy ﬁbroblasts (88% Tra-1-60 positive). CCMi002BMD-A-9 dif-
ferentiated into all three germ layers in vitro as indicated by immunocy-
tochemistry showing expression of the ectodermal marker nestin; the
mesodermal marker alpha-smooth muscle actin (α-SMA), and the en-
dodermal marker Sox17 (Fig. 1D). CCMi002BMD-A-9 was karyotypi-
cally normal at P15 and P21 as determined by the analysis of 30
metaphases which showed normal size, shape, and number of chromo-
somes (Fig. 1E). The identity of CCMi002BMD-A-9 was conﬁrmed by
multiple ligation probe ampliﬁcation (MLPA) of DNA extracted from
CCMi002BMD-A-9 which was compared to a control iPSC line (derived
from a healthy control subject's dermal ﬁbroblasts). Maintenance of theFig. 1.Derivation of the Becker muscular dystrophy induced pluripotent stem cell line CCMi002
morphology.B Expression of SSEA4 andTra-1-60 pluripotency-associatedmarkers inCCMi002B
large percentages of cells in CCMi002BMD-A-9 Δ45-55 and a Control iPSCline expressed th
representative FACS analysis histogram (Control v CCMi002BMD-A-9 Δ45-55, values are repr
assay revealed that CCMi002BMD-A-9 Δ45-55 was capable of differentiation into all three
karyotype without any measurable anomalies. F Multiplex ligation-dependent probe am
electropherograms) while CCMi002BMD-A-9 Δ45-55 presented deletions of DMD exons fromDMD reading framewas conﬁrmedby the presence of a large deletion of
exons 45 to 55 (CCMi002BMD-A-9 Δ45-55; Fig. 1F).Materials and methods
Reprogramming of BMD patient's ﬁbroblasts to iPSCs
All investigations were conducted according to the principles stated
in the Declaration of Helsinki. Following informed consent under the
regulations of the local ethics committee (European Institute of Oncol-
ogy and Centro Cardiologico Monzino, Italy) the patient's ﬁbroblasts
were isolated from a skin biopsy by explant culture. Fibroblasts were
transfected with episomal vectors (pCXLE-hUL, pCXLE-hSK, pCXLE-
hSK, pCXLE-hOCT4; Addgene) by electroporation (Neon™ transfection
system, Invitrogen), transferred into a single well of a 6 well plate pre-
coated with human recombinant vitronectin (Life Technologies) and
cultured at 37 °Cwith 5% CO2. On day 3 post transfection transfected ﬁ-
broblasts were transferred to a reprogramming media (ReproTeSR™,
Stemcell Technologies) which was replaced every day. Colonies were
harvested when they reached 1000 μm in diameter bymanual isolation
using a 25 gauge sterile syringe and transferred into an individual well
of a 12-well plate containing mTeSR1™media (Stemcell Technologies)
supplemented with RevitaCell™ (Life Technologies). iPSCs were main-
tained in mTeSR1™ media with daily media changes. At 80–90%
conﬂuency, iPSCs were non-enzymatically passaged (every 3–4 days)
with ReLeSR™ (Stemcell Technologies) and replated as small aggre-
gates in mTeSR1™ media containing RevitaCell™. Stock vials of iPSCs
were harvested in mFreSR™ (Stemcell Technologies) and stored at
-180 °C for future experiments.Pluripotency marker immunocytochemistry
For the analysis of pluripotency protein expression, SSEA4 and Tra-
1-60 were detected using commercially available antibodies. iPSCs
were analysed with a confocal microscope (Zeiss LSM710). All primary
and secondary antibody details are listed in Table 2.BMD-A-9 Δ45-55. A Representative transmitted light images showing the pluripotent cell
MD-A-9Δ45-55was determinedby immunoﬂuorescence staining. C FACS analysis showed
e pluripotency marker Tra-1-60 as indicated above by the summary data graph and a
esented as mean ± SEM, Student’s t test, n = 3). D An in vitro trilineage differentiation
germlayers. E Karyogram from CCMi002BMD-A-9 Δ45-55 displaying a normal 46, XY
pliﬁcation assay (MLPA) revealed a normal DMD genotype for Control iPSCs (lower
45 to 55 (upper electropherograms) that is consistent with an in-frame mutation.
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Table 2
RRID Requirement for antibodies: use http://antibodyregistry.org/ to retrieve RRID for antibodies and include ID in table as shown in examples.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-SSEA4 1:200 Abcam Cat# ab16287, RRID:AB_778073;
Mouse anti-Tra-1-60 1:200 (IFC)
1:100 (FACS)
Abcam Cat# ab16288
RRID: AB_ AB_778563;
Differentiation markers
(DM)
Mouse anti-Nestin 1:100 Stemcell Technologies Cat# 60091AD, RRID:AB_2650581;
Rabbit anti-Sox17 1:100 Cell Signaling Inc. Cat#81778, RRID:AB_2650582;
Mouse anti-αSMA 1:100 Millipore Cat# CBL171, RRID:AB_2223166;
Secondary antibodies Anti-Mouse IgG, Alexa®Fluor 488 1:400 (for SSEA4) Thermo Fisher Scientiﬁc Cat# A11059, RRID:AB_2534106;
Anti-Rabbit IgG, Alexa®Fluor 488 1:200 (for Sox17) Thermo Fisher Scientiﬁc Cat# A11034, RRID:AB_2576217;
Anti-Mouse IgM, Alexa®Fluor 488 1:400 (for
Tra-1-60)
Thermo Fisher Scientiﬁc Cat# A21042, RRID:AB_
AB_2535711;
Anti-Mouse IgG2a Cross-Adsorbed Secondary Antibody, Alexa®Fluor
633
1:200 (for αSMA) Thermo Fisher Scientiﬁc Cat# A-21136, RRID:AB_2535775;
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CCMi002BMD-A-9Δ45-55 were dissociated using Gentle Cell Disso-
ciation Reagent (Stemcell Technologies). Non-speciﬁc staining was
blocked using 5% Bovine Serum Albumin (BSA; Sigma-Aldrich) in PBS
(Lonza). Cells were stained with a Tra-1-60 (1:100, 1 h; ab16288
Abcam) per reaction followed by goat anti-mouse IgM-FITC (1:200,
1 h; A21042 Life Technologies). Cells were analysed using a
FACSCalibur™ (BD Biosciences) and Gallios (Beckman Coulter) ﬂow
cytometers.
In vitro trilineage differentiation potential assay
CCMi002BMD-A-9Δ45-55 iPSCs were cultured and differentiated as
per the manufacturer's instructions (STEMdiff™ trilineage differentia-
tion kit, Stemcell Technologies). All primary and secondary antibodyde-
tails are listed in Table 2.
Karyotyping
Metaphase chromosomes were prepared from CCMi002BMD-A-9
Δ45–55 cultures at passage 15 and 21. After 48–96 h colcemid (10 μg/
ml) was added directly to the cultures and incubated for 3 h at 37 °C.
iPSCs were incubated in hypotonic solution (Sodium Citrate 0.6%, KCl0.13%) at room temperature for 10 min, washed with Ibraimov solution
(acetic acid 5%), ﬁxed in Optichrome (28 °C, 42% rH) with methanol/
acetic acid (3:1), Q-banded and photographed. Karyotype images
were obtained at 100× magniﬁcation (Immersion oil: Immersol 518N,
Zeiss) using a Olympus BXmicroscope connected to a U-CMAD3 Olym-
pus camera. 30metaphases were analysed and karyotyped using an au-
tomated cytogenetic imaging system (MetaSystems Gmbh, Germany).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.01.025.
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